Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss

Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane^® Lyfttm or Contourtm in combination with Sculptra^® in patients with medication-driven weight loss with associated facial volume loss.¹ Initial three-month interim data from this first-of-its-kind trial suggest that this treatment combination effectively improved facial aesthetic appearance with high patient satisfaction.¹ The results will be presented later today at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.^2-4 Patients can find that their skin is less radiant, drier or saggy, and can also observe changes in their facial structure and balance.^3,4 Some even find that they appear older than their age.^3,4 There are several reasons for these facial alterations including loss of fat, collagen, elastin and essential nutrients such as fatty acids.⁴

Three-month interim data provide response to one of the most predominant aesthetic concerns of patients taking prescription weight loss medicines

In a phase IV clinical trial conducted in the U.S., Galderma investigated the efficacy, safety, and patient satisfaction of Restylane Lyfttm or Contourtm in combination with Sculptra for cheek augmentation and correction of contour deficiencies in patients with medication-driven weight loss with associated facial volume loss.¹ Informed by insights gained from pivotal trials of Sculptra and the Restylane portfolio, the trial took place across two sites and used the SHAPE Up Holistic Individualized Treatment (HITtm) as a treatment methodology.¹ HITtm is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction.

Patients were treated with Sculptra and either Restylane Lyfttm or Contourtm for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyfttm or Contourtm at Week 4, and an optional third treatment of Sculptra at Week 8.¹ Follow-up visits took place at Week 20 for those who received the third Sculptra treatment and at Week 16 for those who did not, corresponding to three months after their final treatment.¹

Results at three months demonstrated that the combination of Sculptra and Restylane Lyfttm or Contourtm effectively improved the facial aesthetic appearance of patients experiencing significant medication-driven weight loss with associated facial volume loss, further supporting the benefits of the SHAPE Up HITtm:¹

• Three months after their final treatment, subjects showed improved mid-face shape and contouring along with improvements in cheek wrinkles and an overall improvement in facial appearance¹
• Skin quality findings, which were assessed and reported in the Sculptra/Restylane Lyfttm regimen, demonstrated improvements beyond visual improvement; with Sculptra significantly improving skin radiance and skin thickness three months after final injection treatment¹
  • Additionally, results showed Restylane Lyfttm significantly improved skin hydration as early as Week 4, which was maintained at the three-month follow-up visit¹
• Subjects reported high satisfaction as early as four weeks after their first treatment session, which was maintained through to three months after their treatment¹
  • At Week 4, 85% said their face looked more refreshed, and almost 80% noticed their facial balance was improved, and said the SHAPE Up HITtm enhanced their face's structural harmony¹
  • 89% felt more attractive and happier with their appearance and agreed it provided natural looking results at three months post follow-up¹

Safety was in line with previous pivotal trial data for all products, with no treatment-related adverse events reports.¹

Galderma's broad portfolio addresses key patient and healthcare professional needs

Galderma is well-positioned to address these alterations, given its expertise and experience in dermatology, specialized range of injectable treatments and skincare products, and its patient-centric approach, developed in close collaboration with leading healthcare professionals. While Sculptra - the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCAtm) formulation - can help to restore skin integrity, our portfolio of Restylane hyaluronic acid injectables can help refine areas of the face that may have been altered during the weight loss journey.^1,5-9

A six-month extension is now ongoing to confirm the long-term effects, a full nine months after final Sculptra treatment, to further confirm the benefits of the combination approach.

About the study
This phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane^® Lyfttm or Contourtm in combination with Sculptra^® for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists.¹ Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HITtm) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyfttm or Contourtm for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyfttm or Contourtm at Week 4, and an optional third treatment of Sculptra at Week 8.¹ Follow-up visits took place at Week 20 for those who received the third Sculptra treatment and at Week 16 for those who did not.¹ Skin quality findings were assessed in the Sculptra/Restylane Lyfttm regimen.¹

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ ? the skin ? meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1. Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies.
2. Mansour MR, et al. The rise of "Ozempic Face": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/j.bjps.2024.07.051
3. Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057
4. Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721
5. Sculptra^®. EU Instructions for Use. 2021. Available online. Accessed January 2025
6. Widgerow A, et al. A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress, February 1-3, 2024, Paris, France
7. Galderma. Data on File (MA-60875)
8. Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042
9. Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.779